Arilvax: Began Phase III trial

Peptide Therapeutics Group plc (LSE:PTE), Cambridge, U.K. Product: Arilvax Business: Infectious diseases Therapeutic category: Immune stimulation, Viral infection Target: Yellow fever virus Descripti...